### TABLE 1—Continued

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA 085720</td>
<td>Meprobamate Tablets USP, 200 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 085721</td>
<td>Meprobamate Tablets USP, 400 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 085778</td>
<td>Hydroxyzine HCl Injection USP, 25 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086096</td>
<td>Chlorpheniramine Maleate Injection USP, 10 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086189</td>
<td>Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086598</td>
<td>Nandrolone Decanoate Injection USP, 100 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086795</td>
<td>Chlorothiazide Tablets USP, 250 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087183</td>
<td>Ergoloid Mesylates Sublingual Tablets USP, 1 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087296</td>
<td>Chlorthalidone Tablets USP, 25 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087521</td>
<td>Chlorthalidone Tablets USP, 50 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087772</td>
<td>Prednisone Tablets USP, 50 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087979</td>
<td>Chloroquine Phosphate Tablets USP, EQ 150 mg base</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088030</td>
<td>Chloroquine Phosphate Tablets USP, EQ 300 mg base</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 089042</td>
<td>Procainamide HCI Extended-Release Tablets USP, 750 mg</td>
<td>Do.</td>
</tr>
</tbody>
</table>

Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of November 24, 2017. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Dated: October 18, 2017.

Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–23046 Filed 10–23–17; 8:45 am]
BILLING CODE 4164–01–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44).

Date: November 17, 2017.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E70, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5020, varthakavivi@niaid.nih.gov (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS).

Dated: October 18, 2017.

Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–22967 Filed 10–23–17; 8:45 am]
BILLING CODE 4140–01–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; International Research Ethics Training.

Date: November 16, 2017.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Karin F. Helmers, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 451–9975, helmersk@csr.nih.gov (Virtual Meeting).

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR16–121 Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (ROI).

Date: November 16, 2017.

Time: 12:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451–6319, rojasr@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Macromolecular Structure and Function.

Date: November 20, 2017.

Time: 1:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: C-L Albert Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3E70, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 669–5020, varthakavivi@niaid.nih.gov.
Supplementary Information:

Notice of Advisory Council on Historic Preservation Quarterly Business Meeting


Summary: Notice is hereby given that the Advisory Council on Historic Preservation (ACHP) will hold its next quarterly meeting on Thursday, November 9, 2017. The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE., Washington, DC, starting at 8:30 a.m.

Dates: The quarterly meeting will take place on Thursday, November 9, 2017, starting at 8:30 a.m.

Addresses: The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE., Washington, DC.

For Further Information Contact: Cindy Bienvenue, 202–517–0202, cbienvenue@achp.gov.

Supplementary Information: The Advisory Council on Historic Preservation (ACHP) is an independent federal agency that promotes the preservation, enhancement, and sustainable use of our nation’s diverse historic resources, and advises the President and the Congress on national historic preservation policy. The goal of the National Historic Preservation Act (NHPA), which established the ACHP in 1966, is to have federal agencies act as responsible stewards of our nation’s resources when their actions affect historic properties. The ACHP is the only entity with the legal responsibility to encourage federal agencies to factor historic preservation into their decision making. For more information on the ACHP, please visit our Web site at www.achp.gov.

The agenda for the upcoming quarterly meeting of the ACHP is the following:

I. Chairman’s Welcome
II. Section 106 Issues
   A. Administration Infrastructure Initiatives
   B. ACHP Response to Recent Natural Disasters
   C. Proposed Exemption Regarding Railroad and Rail Transit Rights of Way
   D. ACHP Report to the President Pursuant to Executive Order 13287
   E. Development of an Online Section 106 Forum
   F. ACHP Regulatory Review Progress
III. Historic Preservation Policy and Programs
   A. Policy Statement on Commemorative Works
   B. ACHP Recommendations for the Future of the National Historic Preservation Program
   C. Historic Preservation Legislation in the 115th Congress
   D. ACHP Speakers’ Bureau Proposal
   E. ACHP/HUD Historic Preservation Award Follow Up
   IV. New Business
   V. Adjourn

The meetings of the ACHP are open to the public. If you need special accommodations due to a disability, please contact Cindy Bienvenue, 202–517–0202 or cbienvenue@achp.gov, at least seven (7) days prior to the meeting. Authority: 54 U.S.C. 304102.

Dated: October 18, 2017.

Javier E. Marques, General Counsel.

Public Participation and Request for Comments

This Notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection’s purpose, the Collection’s likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection. The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection, (2) the accuracy